

Definition, manufacture, assessment and handling post-approval changes

12 - 13 February 2015, Barcelona, Spain

SPEAKERS:

Hiltrud Horn

Horn Pharmaceutical Consulting, Germany

Corina Nachtsheim

Quality Assessor

Matthias Schneider

BASF, Germany

Francois Vandeweyer

Janssen Pharmaceutica, Belgium

PROGRAMME:

- Defining an API Starting Material
- Starting materials in the CEP application procedure
- Re-defining regulatory starting materials and how to deal with it
- Risk assessment and criticality analyses
- Quality agreements
- Handling post approval changes
- Pre-starting material information



API Regulatory Starting Materials

12 - 13 February 2015, Barcelona, Spain

Objectives

During this course **all relevant aspects** regarding API regulatory starting materials will be discussed. You will learn

- What has to be considered when a starting materials have to be defined
- How risk assessment can be applied
- Which aspects have to be taken into account when applying for a CEP
- How quality agreements should look like and
- How post approval changes can be handled.
- Furthermore you will have the opportunity to one of two parallel workshops about
- How to identify and control CQAs of starting materials in API synthesis
- How to handle Changes to Starting Materials specifications

Background

According to EU GMP Guide Part II (ICH Q7) an API starting material is a raw material, an intermediate, or an API that is used in the production of an API and is incorporated as a significant structural fragment into the structure of the final API. From this point on, appropriate GMP has to be applied to the API manufacturing steps.

In a marketing authorisation application the applicant has to describe in an ASMF the API manufacturing process. The "API regulatory starting material" has to be clearly designated and the rationale for the point at which the production of the API begins has to be documented. The same applies for a CEP application procedure.

In the last few years assessors have been more and more challenging the proposed regulatory starting materials. E.g. the definition of a starting material has been one of the top deficiencies in CEP applications. This is partly due to the fact that companies tend to describe shorter synthetic routes starting from complex starting materials. Moreover changes of critical quality attributes and the request from the authorities to re-define the starting material can create difficult situations regarding additional efforts and significant delays in the application process.

Target Audience

This course is designed for all persons involved in the manufacture of APIs. Furthermore, the seminar will be of interest to personnel from quality assurance, regulatory affairs both from API and pharmaceutical companies and to contract manufacturers.

Programme

How to define API Regulatory Starting Materials: What do the guidelines tell us?

- API Regulatory Starting Materials overview of guidelines
- Definition according to the guidelines
- Global guidelines (ICH Q7 and Q11)
- US, EU and Japan guidance
- How to use the term "significant structural fragment"
- Distinguishing starting meterials from raw materials, reagents and solvent
- Selection of an appropriate Starting Material
- Starting Material specification

API Regulatory Starting Materials - Challenges and practical implications

- How to use the elements of the guidelines in practice
- Is a global approach the best way forward?
- What is the level of detail to be provided?
- What are the consequences of the choice?

Starting Materials and the CEP application procedure

- Regulatory background
- Scope of the CEP procedure
- Provisions of the Guideline PA/PH/CEP (14) 06 "Use of a CEP to describe a starting material in an application for another CEP"
- Important points to be considered for defining an API starting materials

From starting materials to APIs: risk assessment and criticality analyses

- Criticality analysis methods (HAZOP, FMEA etc)
- Critical quality attributes (CQA) and critical process steps (CPS)
- Linking CQA and synthesis steps
- Critical impurities
- Critical raw materials
- Process criticality analysis; example

Reservation Form (Please complete in full)

If the bill-to-address deviates from the specifications on the right,

please fill out here:

13 February 2015, Barcelona, Spain

Regulatory Starting Materials

API

Reservation Form: CONCEPT HEIDELBERG P.O. Box 10 17 64



e-mail: info@concept-heidelberg.de



Germany

Please choose ONE workshop: ☐ API synthesis: How to identify and control CQAs of starting materials ☐ Changes to Starting Materials	Mr. Ms.	Title, first name, surname	Company Department	Important: Please indicate your company's VAT ID Number Purchase Order No, if applicable	Street/P.O. Box	City Zip Code Country	Phone/Fax	E-Mail (please fill in)

Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg

GERMANY

CONCEPT HEIDELBERG

P.O. Box 101764

processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my In case you do not appear at the event without having tas, you will have to pay the full registration fee, even if too made the payment yet. Only after we have received ment, you are entitled to participate in the conference of payment will not be confirmed)! (As of January 2012)

message. In case you do n informed us, you will have you have not made the ps your payment, you are en (receipt of payment will n

structors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deduc-

tions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part,

Date

Thursday, 12 February 2015, 9.00 - 17.45 h (Registration and coffee 8.30 – 9.00 h) Friday, 13 February 2015, 8.30 - 14.30 h

Venue

Barceló Sants Placa dels Paisos Catalans, s/n Estació de Sants 08014 Barcelona, Spain Phone +34 93 503 53 00 +34 93 490 60 45

Fees (per delegate plus VAT)

ECA Members € 1,590 APIC Members € 1,690 Non-ECA Members € 1,790 EU GMP Inspectorates € 895

The fee is payable in advance after receipt of invoice and includes conference documentation, social event and dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

Accommodation

CONCEPT has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form / POG when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG P.O. Box 10 17 64 D-69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0 Fax +49 (0) 62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content:

Dr Gerhard Becker (Operations Director) at +49 (0) 62 21 / 84 44 65, or per e-mail at becker@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Ms Susanne Ludwig (Organisation Manager) at +49 (0) 62 21 / 84 44 44, or per e-mail at ludwig@concept-heidelberg.de.

CONCEPT HEIDELBERG reserves the right to change the materials, prior to the conference 100 %

If you cannot attend the conference you have two options:

I. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge
the following processing fees: Cancellation

- until 2 weeks prior to the conference 10%, - until 2 weeks prior to the conference 10 %, - until 1 weeks prior to the conference 50 %

wa/vers1/16102014

Workshops

- API synthesis: How to identify and control CQAs of starting materials
- Changes to Starting Materials



Quality agreements with RSM suppliers

- Objectives and contents of Quality Agreements
- Negotiations of Quality Agreements who should be involved?
- Notification of changes
- Quality agreements concerning starting materials that have also non-pharmaceutical uses

How to handle post-approval changes

- Changes to the pre-starting material information
- Re-definition of the starting material: possible or not
- Handling changes/variations when multiple stakeholders are involved

APIC's perspective on Starting Materials

- APIC's position on
 - Definition of the SM
 - Risk management
 - Qualification of the SM supplier
 - Pre-SM information
 - Handling changes/variations

Speakers



Dr Hiltrud Horn Horn Pharmaceutical Consulting, Germany

From 1990 to 1997, she was employed by Hoffmann-La Roche in Quality Control/Quality Assurance. From 1997 to 1999, she dealt with medical writing in the 'In-

ternational Drug Regulatory Affaires and Project Management' department of the same company. In 1999, she joined Knoll AG as head of the departments 'Regulatory Compliance and CMC Documentation' and 'Dossier Production and Compliance' for international drug registration. In 2002, she started at Cap Gemini Ernst & Young, where she was the responsible consultant for questions concerning biotechnology and life sciences.



Dr Corina Nachtsheim Quality assessor, Germany

Dr. Nachtsheim studied chemistry at the University of Cologne and received a Ph.D. (Dr. rer. nat.) in pharmaceutical chemistry at the University of Bonn. She is working as a quality assessor at the

German Federal Institute for Drugs and Medical Devices since Jan. 2001. Since Nov. 2007, she is an external expert in the framework of the certification procedure of the EDQM in Strasbourg. She became a member of the chemical Technical Advisory Board (EDQM) in Nov. 2011 and is currently chairperson.

Matthias Schneider BASF, Germany



Francois Vandeweyer

Janssen Pharmaceutica, Belgium
Francois Vandeweyer joined Janssen
Pharmaceutica (part of Johnson & Johnson) in 1981 in chemical development.
Until 1995 increasing responsibilities
within the organisation mainly in the

Quality Control Unit. Starting from 1995 he joined the QA department. Several Senior Manager responsibilities. 2005 Sr Manager GMP Compliance Chemical Operations Belgium (sites Geel – Olen – Beerse). 2009 Director Global Compliance EMEA/AP for Johnson & Johnson.

Social Event



On 12 February, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.